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Abstract
Background: A community-based occupational therapy intervention for people with mild to moderate dementia
and their family carers (Community Occupational Therapy in Dementia (COTiD)) was found clinically and cost
effective in the Netherlands but not in Germany. This highlights the need to adapt and implement complex
interventions to specific national contexts. The current trial aims to evaluate the United Kingdom-adapted
occupational therapy intervention for people with mild to moderate dementia and their family carers living in the
community (COTiD-UK) compared with treatment as usual.
Methods/Design: This study is a multi-centre, parallel-group, pragmatic randomised trial with internal pilot. We aim
to allocate 480 pairs, with each pair comprising a person with mild to moderate dementia and a family carer, who
provides at least 4 hours of practical support per week, at random between COTiD-UK and treatment as usual. We
shall assess participants at baseline, 12 and 26 weeks, and by telephone at 52 and 78 weeks (first 40 % of recruits
only) after randomisation. The primary outcome measure is the Bristol Activities of Daily Living Scale (BADLS) at 26
weeks. Secondary outcome measures will include quality of life, mood, and resource use. To assess intervention
delivery, and client experience, we shall collect qualitative data via audio recordings of COTiD-UK sessions and
conduct semi-structured interviews with pairs and occupational therapists.
Discussion: COTiD-UK is an evidence-based person-centred intervention that reflects the current priority to enable
people with dementia to remain in their own homes by improving their capabilities whilst reducing carer burden.
If COTiD-UK is clinically and cost effective, this has major implications for the future delivery of dementia services
across the UK.
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Background
The G8 Summit on Dementia in 2013 pledged to improve
life and care for people with dementia and their carers,
prevent and delay dementia, and facilitate social adaption
to global ageing and dementia [1]. There are 850,000
people living with dementia in the United Kingdom, of
whom two-thirds live in the community [2]. Dementia
currently costs the UK £26 billion (bn) per year, including
£11 bn of unpaid support provided by 670,000 family
members and friends. Government policy emphasises the
need for high quality, evidence-based interventions [3–6].
Personalised interventions can improve the well-
being of family carers, delay admission to care homes,
and reduce the risk of institutionalisation by up to one-
third [7, 8]. Despite little robust evidence, the NICE-
SCIE practice guideline for supporting people with de-
mentia and their carers recommends advice and skills
training from an occupational therapist to help those
affected to maintain independence [9]. In the Netherlands,
Graff et al. [10] developed a clinical guideline for Commu-
nity Occupational Therapy in Dementia (COTiD) in
which they recommended 10 one-hour sessions of home-
based occupational therapy over 5 weeks in partnership
with the person who has mild to moderate dementia and
their family carer to improve skills in the activities of daily
living (ADL) and the carer’s abilities and sense of compe-
tence. A randomised controlled trial (RCT) of COTiD
versus treatment as usual demonstrated improved ADL
skills, quality of life, mood and health status, and de-
creased the need for assistance for the people with de-
mentia; improved sense of competence, quality of life,
mood, and health status for their carers [11, 12]; and
improved the cost effectiveness [13]. However a subse-
quent RCT in Germany found no difference between
providing COTiD or a single consultation potentially
due to the lack of cultural adaptation of the interven-
tion [14]. This highlights the need to adapt complex in-
terventions to specific national contexts [15]. Although
COTiD appears to have potential for wider implemen-
tation, we therefore need to translate and make it suit-
able for the UK before evaluating it in a RCT within
the Valuing Active Life in Dementia (VALID) research
programme.
VALID aims to adapt, develop, evaluate, and imple-
ment an occupation-based intervention to improve in-
dependence, meaningful activity, and quality of life for
people with mild to moderate dementia and their family
carers living in the community. The programme struc-
ture is based on the Medical Research Council’s (MRC)
‘Framework for development and evaluation of RCTs for
complex interventions to improve health’ [16], which de-
scribes four phases: development, feasibility and pilot-
ing, evaluation, and implementation. The VALID
development phase sought to develop the COTiD-UK
intervention for subsequent evaluation in an RCT. Ac-
tivities included translating the Dutch materials; train-
ing 44 occupational therapists, who put COTiD-UK
into practice with 130 pairs; running focus groups and
a consensus event; and conducting a national on-line
survey to scope current UK occupational therapy prac-
tice and service provision for people with mild to mod-
erate dementia and their family carers living in the
community.
This RCT aims to estimate the clinical and cost-
effectiveness of the COTiD-UK intervention in compari-
son with treatment as usual (TAU).
A CONSORT-style flowchart of the trial is shown at
Fig. 1.
Methods/Design
Design
This study is a multi-centre, parallel-group, pragmatic
randomised trial with internal pilot to estimate the clin-
ical and cost effectiveness of COTiD-UK relative to
treatment as usual (TAU). We shall recruit pairs of
people with mild to moderate dementia and an identified
family carer. We shall allocate recruited pairs at random
to TAU and the COTiD-UK intervention in addition to
TAU (which may or may not include occupational
therapy provision).
The primary outcome measure is the Bristol Activ-
ities of Daily Living Scale (BADLS) [17], with a pri-
mary end point of 26 weeks. This is considered the
optimal time to assess the benefit of COTID-UK on
the BADLS whilst reducing the risk of dropout with
longer follow-up.
An internal pilot will precede the full RCT to test the
outcome measures and trial procedures and to finalise
the modes of COTiD-UK delivery, training, and occupa-
tional therapist supervision, with the intention of mov-
ing forward into the full trial. We shall recruit and
randomise 50 pairs for the pilot and use predefined
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criteria within the ACCEPT framework [18] to review
the pilot trial. If the criteria are met to the satisfaction
of the independent Programme Steering Committee,
the study will proceed to the full trial, by recruiting
and randomising another 430 pairs to give a total of
480 pairs. Protocol modifications as approved by the
Sponsor will be communicated as appropriate to the
Ethics Committee, sites, and participants.
Recruitment:
Dyads living in the community and meeting the eligibility 
criteria are approached through health and social care 
services using:
Study promotional posters and leaflets
Study information leaflet with reply slip
Informed consent obtained
Excluded:
Not meeting inclusion criteria 
Declined to participate 
Other reasons 
Telephone interviews with a 
sample of dyads that declined 
taking part
12 week follow-up
Record and list of those lost to follow-up and reasons why if given
Community Occupational Therapy in Dementia-UK 
n = 256
10 hours of COTiD-UK intervention 
Treatment as Usual (Control) Group n = 224
Baseline assessment
n = 480
Randomised n = 480
26 week follow-up
Primary end point
Extended follow-up
52 week telephone follow-up with all participants – serious adverse events, CSRI, EQ-5D-5L, 
HADS
78 week telephone follow-up with participants recruited in first 6 months (40% of total sample) 
as above
Fig. 1 VALID trial flowchart
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NHS ethical approval was obtained from the NRES
Committee London - Camberwell St Giles (reference
number 14/LO/0736).
Setting
The study will run in twelve NHS sites across England.
Participating organisations must routinely provide health
or social care services to people with mild to moderate
dementia and their family carers; employ occupational
therapists who work with this population; protect the
time needed for at least two occupational therapists to
complete the COTiD-UK training, achieve competency
and deliver the intervention to ten pairs each; identify a
local Principal Investigator; and obtain support from
their local Research & Development department and
Clinical Research Network to complete all the research
activities described in this protocol.
Participants will primarily be recruited from older
adult mental health services, notably memory services,
but other avenues may be applicable in some areas, for
example, liaison psychiatry services or voluntary organi-
sations. We define a family carer as ‘the primary person
who feels responsible for, and provides practical support
(personal and/or domestic) to, a person with dementia
for a minimum of four hours per week. These need not
be the closest family member; they could be an extended
family member, a close friend, or neighbour and can live
together or separately’.
Participants
Inclusion criteria
Participants with dementia must live in their own home
(including sheltered accommodation but not a care
home), have a diagnosis of dementia as defined by the
DSM-IV [19] and score between 0.5 and 2 on the Clinical
Dementia Rating Scale [20], be able to converse in English,
be able and willing to participate in the COTiD-UK inter-
vention in partnership with their carer, and have the cap-
acity to provide consent. Carers must be aged 18 or
over, provide practical support with domestic and/or
personal activities to the person with dementia for a
minimum of 4 hours per week; and fulfil analogous
criteria. Pairs will not be eligible if either is partici-
pating in another intervention study.
Occupational therapist participants will be registered
as an occupational therapist with the UK Health and
Care Professions Council and have experience working
in the community or with people who have dementia
and their family carers.
Recruitment
Sites and occupational therapists
Recruitment of sites will be via professional and research
networks, including the UK National Institute for Health
Research (NIHR) Clinical Research Network. Interested
organisations will complete a site feasibility checklist to
confirm that they meet the inclusion criteria and that
adequate resources are available to complete the study
in that site. Participating sites will then recruit occupa-
tional therapists who meet the inclusion criteria defined
above.
People with dementia and their carers
We shall brief the clinical staff within the participating
services about the study and provide recruitment posters
and initial invitation leaflets for potential participants.
Research staff will follow a defined screening process to
check eligibility, provide the Participant Information
Sheet, and complete the recruitment process. The trial
recruitment documents were prepared in consultation
with people who have dementia and carers in order to
maximise accessibility. All recruitment documents and
processes are designed to ensure that those with cogni-
tive impairment are fully informed using appropriate
language and materials and are engaged in the decision
to take part. Strategies include the language and format
used in documents, research staff meeting people face to
face rather than telephoning, and allowing the time
needed to explain the trial to potential participants in
order to enable informed choice. It is also important that
all research staff members understand the needs of, and
are trained to communicate effectively with, this popula-
tion. All trial participants will receive the VALID News-
letter published every 6 months to keep them informed
of the study.
Consent process
Informed consent will be obtained from all participants.
As people with mild to moderate dementia will be in-
vited to participate, it is anticipated that they will have
capacity to understand the implications of taking part
and so be able to provide their informed consent, pro-
vided sufficient time is taken to explain and appropriate
methods of communication are used. The British
Psychological Society guidance on evaluating capacity to
consent [21] will be followed. As such, obtaining consent
is seen as a continuing process, not a one-off decision. It
is possible that a person with dementia will lose capacity
during the course of the study. If this occurs, then the
provisions of the Mental Capacity Act and the associated
guidance on nominating a Consultee [22] will be
followed. The family carer who is participating in the
trial cannot act as the Consultee.
To assess generalisability, each site will maintain a log
of people who satisfy the entry criteria for the trial but
are not recruited, including basic demographic and clin-
ical details and reasons for not consenting to participate
if known.
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Interventions
Community Occupational Therapy in Dementia (COTiD-UK)
This manualised intervention consists of up to 10 hours
of community occupational therapy for the person with
dementia and his or her defined carer. Each pair works
in partnership with an occupational therapist to identify
meaningful activities and to set appropriate intervention
goals. In the first phase, the occupational therapist col-
lects information about both parties and the environ-
ment within which the person with dementia lives,
including a narrative interview of approximately 1 hour
with each individual and observation of the environment
and of the person with dementia completing an activity
to observe the strategies used by the person with de-
mentia and the carer’s coping style. The occupational
therapist facilitates a discussion to agree and prioritise a
list of goals to be addressed during the intervention
phase. Goals may be joint or individual to either party
and can be suggested by any of the three parties. The
pair, supported by the occupational therapist, then works
through the agreed goals during the intervention phase
to enhance the ability of the person with dementia to
carry out every day and valued activities. The occupa-
tional therapist also coaches the carer to improve their own
problem-solving skills and coping strategies to enable the
person with dementia to carry out activities and minimise
their care burden, thereby better meeting their own needs.
The sessions usually take place where the person with de-
mentia lives but, depending on the activities chosen, may
also happen in the local community, for example, the sports
club, cinema, or garden centre. The intervention typically
takes up to 10 hours over 5 to 10 weeks.
Treatment as usual
The control group will receive standard clinical care but
not COTiD-UK or any occupational therapy beyond what
they would ordinarily receive. Because the services available
to people with dementia and their carers vary between and
within sites, each participating site will complete a checklist
to describe what they usually provide.
Each participating OT will complete the OT Diary
Tool [23] before starting to provide COTiD-UK to de-
scribe a ‘typical’ week and for one week whilst providing
COTiD-UK. This data will enable comparison of what is
provided as usual treatment versus COTiD-UK.
Fidelity assessment
Fidelity checks to assess how well the delivered COTiD-
UK programme adheres to the intervention manual cover
five domains: study design, provider training, intervention
delivery, intervention receipt, and intervention enactment
[24, 25]. Strategies to maximise intervention fidelity
include a standardised training programme provided
by a consistent team of trainers to the occupational
therapists and those supervising them locally and a
manual outlining the COTiD-UK ‘active ingredients’
and core intervention materials. Occupational thera-
pists will complete a COTiD-UK Checklist to quantify
the number, frequency, length, and content of the ses-
sions provided to each pair. Feedback will be provided
by the trainers to support skill development, and regu-
lar supervision will be provided by a local COTiD-UK
supervisor. We shall audio record COTiD-UK sessions
and transcribe a sample to monitor the occupational
therapists’ adherence to the intervention, using a
checklist derived from the original study.
Outcome measures
The schedule of outcome measures and assessment
points are provided in Fig. 2.
Primary outcome measure
Bristol Activities of Daily Living Scale The Bristol
Activities of Daily Living Scale (BADLS) [17] measures
ability of the person with dementia to complete personal
and instrumental activities of daily living. It is a carer
rated scale that comprises 20 items including dressing,
bathing, food preparation, and using the telephone. Each
item scores between zero and three; a total score of 0
shows independence in all activities. BADLS is valid, re-
liable, and responsive to change over time [26].
Secondary outcome measures for person with dementia
Cognition The Mini Mental State Examination (MMSE)
[27] is a widely used measure of cognitive function,
which is completed by the person with dementia.
Condition-specific quality of life The Dementia Quality
of Life scale (DEMQOL) [28] measures five quality of life
domains: health, wellbeing, cognitive functioning, social
relationships, and self-concept. The person with dementia
completes the 28-item questionnaire, and the carer com-
pletes the 31-item proxy version.
Activities of daily living The Interview of Deterioration
in Daily activities in Dementia (IDDD) [29] measures
the level of assistance required by the person with de-
mentia to complete daily living activities by interviewing
the carer.
Mood The Cornell Scale for Depression in Dementia
(CSDD) [30] screens for depression in people with de-
mentia by interviewing the person with dementia or
carer as appropriate.
Secondary outcome measures for carer
Sense of competence Sense of Competence Question-
naire (SCQ) [31] measures the carer’s perspective of his/
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her own competence to cope with the person with
dementia.
Mood The Hospital Anxiety and Depression Scale (HADS)
[32] is a widely used measure of anxiety and depression.
Other data collected
Social contact and social activities We will use the in-
terviews to estimate the number of social contacts and so-
cial activities per week as a measure of social functioning.
Serious adverse events We shall record deaths and ad-
verse events that are life threatening, require or extend
hospitalisation, result in disability or incapacity, or are
otherwise considered significant, together with safeguard-
ing alerts, and report them in accordance with Good Clin-
ical Practice.
Economic measures
Resource use The Client Service Receipt Inventory
(CSRI) [33] is used extensively in studies of mental
health and dementia. This inventory gathers data on
accommodation, medication, the use of statutory and
voluntary organisation services, and inputs from carers.
We shall adapt the CSRI to collect resource data from
the carer and thereby estimate the cost of dementia care,
including unpaid carer inputs.
Self-reported health-related quality of life The
European Quality of Life scale – 5 Dimensions 5 Levels
(EQ-5D-5 L) [34] provides a simple descriptive profile
and a single utility for health status which NICE and
many others use to value health-related quality of life.
This scale will be completed by the person with demen-
tia and carer at the baseline and follow-up interviews
and by the carer only at the telephone follow-up(s).
Procedure
Data collection
Research staff masked to the participants’ allocated
group will interview the participants face to face at the
home of the person with dementia – at baseline and 12
and 26 weeks after randomisation. They will also phone
all carers at 52 weeks and again at 78 weeks for those re-
cruited in the first 6 months of the trial to follow up an
estimated 40 % of the total sample for at least 1 year
after the end of the intervention but within the period of
funding. These two phone interviews will collect data on
serious adverse events and allow completion of the CSRI
and carer-rated measures including the BADLS, EQ-5D-
5 L, and HADS.
Randomisation
We shall use a web-based internet clinical trial random-
isation service provided by sealed envelope via the PRI-
MENT Clinical Trials Unit. This will employ permuted
Outcome 
Measure
Time in 
minutes
Data collected from Data collected refer to
Baseline 
interview
Week 12 
interview
Week 26 
interview
52 week 
telephone:
family 
carer only
78 week
telephone:
family 
carer only
Person with 
dementia
Family 
carer
Person with 
dementia
Family 
carer
BADLS 15 
CSRI 20 
MMSE 10 
IDDD 15 
DEMQOL 10 
CSDD 20 
EQ-5D 5 Level 5 
SCQ 15 
HADS 5
Serious 
Adverse Events 5 
Social 
contacts/week 5
Social 
activities/week 5
Fig. 2 Schedule of outcome measures and assessment points. BADLS, Bristol Activities of Daily Living Scale; CSRI, Client Service Receipt Inventory;
MMSE, Mini Mental State Examination; IDDD, Interview of Deterioration in Daily activities in Dementia; DEMQOL, Dementia Quality of Life scale;
CSDD, Cornell Scale for Depression in Dementia; EQ-5D-5 L, European Quality of Life scale – 5 Dimensions 5 Levels; SCQ, Sense of Competence
Questionnaire; HADS, Hospital Anxiety and Depression Scale
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blocks of variable size to stratify participants by site and
allocate them between intervention and control in the
ratio of 1:0.875 to adjust for clustering by occupational
therapist.
An unmasked member of the team at each site will
conduct this randomisation. Participants will receive let-
ters specifying their allocated group, reminding them what
this entails, and enclosing a COTiD-UK information leaf-
let for those in the intervention group. The unmasked
researcher will also inform the relevant COTiD-UK oc-
cupational therapist, who will then contact the pair to
book a first visit to start the intervention within 2 of
randomisation.
Masking
In this ‘single-blind trial’, the research staff collecting
outcome data, statisticians, health economists, the
Programme Steering Committee, and Data Monitoring
and Ethics Committee will be masked to participants’
allocations. However, masking the participants or occu-
pational therapists is not possible. To minimise the risk
of bias [35], we shall take several precautions.
1 We shall stress the importance of maintaining
masking when training research assistants and
occupational therapists and encourage them to raise
any queries they may have.
2 We shall ask pairs not to tell visiting research staff
whether or not they have seen an occupational
therapist.
3 We shall minimise contact between masked
researchers and occupational therapists.
4 Masked research staff will not have access to any
data that could compromise masking, including
specific sections of the web-based database.
5 Masked researchers will record after each
assessment to which group they judged the pair
belonged to and with what level of confidence.
6 We shall record all unmaskings, including the
reason – by participants, researchers, clinical staff or
others.
7 We shall test in sensitivity analysis whether and how
these implicit and explicit forms of unmasking
affected the estimated parameters.
Data management
We shall enter data into a web-based internet clinical
trial data capture system (RedPill) provided by Sealed
Envelope via PRIMENT Clinical Trials Unit. Staff enter-
ing data will each have an individual identifier to access
masked or unmasked sections as appropriate. We shall
audit the accuracy of data according to the agreed-upon
trial monitoring plan. All personal information will be held
securely in accordance with Data Protection legislation.
Sample size
Using a two-sample test and a significance level of 5 %,
172 participants would be required in each arm to detect
a difference between the TAU and COTiD-UK groups of
0.35 standard deviations in mean BADLS scores with 90
% power. Allowing for clustering by OT within the
COTiD-UK arm, and assuming an average cluster size of
10 pairs and an intra-cluster correlation (ICC) of 0.015,
the size of the intervention arm was inflated to 196.
Allowing for 15 % attrition at 6 months (estimated from
previous similar studies), and 5 % non-adherence in-
creases the total sample size required to 480 pairs: 256
intervention and 224 control. We estimated the sample
size using STATA version 11.
Qualitative data collection
We shall collect and analyse a range of qualitative data
to explore the experience of taking part in COTiD-UK,
and the feasibility of implementing it in practice. We
shall analyse a purposive sample of transcripts of audio
recorded COTiD-UK sessions, stratified by the occupa-
tional therapist and type of session. We shall conduct
semi-structured interviews exploring the experience of
providing COTiD-UK with a purposive sample of par-
ticipating occupational therapists, stratified by grade, ex-
perience and service, and sufficient in number to
achieve saturation. We shall develop an indicative topic
guide for these interviews, which will be conducted over
the telephone and recorded.
Semi-structured interviews will explore the experience
of COTiD-UK with a purposive sample of participating
pairs soon after they have completed the COTiD-UK.
We shall stratify interviewed pairs by site, gender, ethni-
city, relationship, and number of COTiD-UK sessions
received, and we will recruit enough to achieve satur-
ation. An indicative topic guide will be used for these re-
corded interviews, which will all be conducted face to
face and separately with the person who has dementia
and with their carer when feasible.
Brief telephone interviews will be conducted with a
sample of carers who declined to take part in the trial.
When a potential participant declines, we shall ask for
their reason and offer the opportunity of discussing this
by phone with a member of the central research team.
We will ask the person to sign a reply slip consenting to
be contacted for a short telephone interview, which will
take no longer than 15 minutes and be audio recorded
to enable analysis.
Statistical analysis
Analysis will follow a defined statistical analysis plan ap-
proved by the independent Data Monitoring and Ethics
Committee before we access any trial data. We do not
plan any interim analysis.
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The baseline characteristics will be presented descrip-
tively for individuals with dementia and their carers.
Categorical variables shall be reported as counts and
percentages and continuous variables as mean/median
and standard deviation/interquartile ranges as appropri-
ate. Primary analysis will use the BADLS scores at 26
weeks to compare the COTiD-UK and TAU groups. We
shall use a random-effects linear regression model to
take account of clustering by occupational therapist in
the COTiD-UK arm, adjusting for the baseline BADLS
score and trial site. We shall investigate potential bias
due to missing data. If we identify predictors of missing-
ness that are related to the outcome, we shall adjust the
primary analysis with these predictors.
We shall also use repeated measurements of the
BADLS score in the secondary outcome analyses using
regression models that account for this additional clus-
tering of measurements within participants. We shall
also investigate the effect of occupational therapists’ ex-
perience, the length of time they have been delivering
the intervention, and the number of COTiD-UK ses-
sions delivered, on BADLS scores using an appropriate
random effects regression model. As part of a sensitiv-
ity analysis, multiple imputation techniques may be
undertaken for the analyses related to the BADLS
score. We shall perform a dose–response analysis to in-
vestigate whether the volume of occupational therapy
contributions in TAU and COTiD-UK arms improve
outcome measures. We shall use appropriate regression
models accounting for clustering to analyse the second-
ary outcomes. We shall check the assumptions of nor-
mality of residuals required by the random effects
models and, if violated, consider appropriate transfor-
mations. Results from the secondary analyses will be
presented as estimates with 95 % confidence intervals,
whereas P-values will be presented only for the primary
comparison. We shall conduct all secondary outcome
analyses by treatment allocated, using available data
only with no adjustment made for missing data. We
shall examine non-adherence in the COTiD-UK group
descriptively, and if appropriate, a complier average
causal effect (CACE) shall be estimated. A detailed
statistical analysis plan will be prepared nearer the
analysis stage (before the data are received for
analysis).
Economic evaluation
We shall analyse cost-effectiveness over the trial period
of 12 months, as we seek to follow all participants for at
least 1 year. We shall also construct a decision-analytic
model to project cost-effectiveness in the long run,
namely the expected lifetime of participants, if the inter-
vention confers significant clinical benefits or cost re-
ductions during the trial period. We shall assess costs
primarily from the perspective of the NHS and personal
social services, but also consider costs to people with de-
mentia and their carers. Thus, we shall cost the COTiD-
UK intervention; NHS resources (including general
practitioners, practice and community nurses, hospital
inpatient, outpatient and day visits for specialist care, oc-
cupational therapy and physiotherapy); personal social
services resources (including social workers, nursing
homes, homecare, meals on wheels and day care); and
informal care (including the time of carers and payments
by people with dementia and carers). We shall derive
unit costs from standard sources.
The short-run model will estimate cost-effectiveness
by the incremental cost per QALY gained and per unit
change in BADLS. We shall estimate QALYs from the
mortality and quality of life data collected during the
trial from EQ-5D-5 L and DEMQOL, including the
proxy version. We shall construct utility profiles for
people with dementia and carers by linear interpolation
and estimate QALYs by the area underneath this profile.
We shall use multiple imputation to infer missing data
on utilities and resource use. We shall estimate cost-
effectiveness by dividing the mean cost difference be-
tween COTiD-UK and TAU by the mean difference in
outcome (in BADLS scores or QALYs) to yield incre-
mental cost-effectiveness ratios (ICER). We shall use
non-parametric bootstrapping to derive confidence in-
tervals for ICERs in the face of data skewness. We shall
construct cost-effectiveness acceptability curves and sub-
ject the results to deterministic sensitivity analysis.
The lifetime model will project cost-effectiveness by
the incremental cost per QALY gained. We shall (1) de-
sign a model to characterise health states of people with
dementia and costs incurred by them and their carers, (2)
populate the model using published literature and routine
sources, (3) extrapolate final outcomes in QALYs from the
trial, and (4) identify which parameters in the model are
the most uncertain drivers of cost-effectiveness. We shall
base the model on existing long-term economic models in
this field. At this stage, we propose a Markovian model of
movement between dementia states every 6 months until
all members of the synthetic cohort have died from de-
mentia progression or other causes.
Qualitative data analysis
We shall use inductive thematic analysis to analyse all
qualitative data including: COTiD-UK session transcripts,
post-intervention interviews, and telephone interviews
with people who declined to participate in the trial. Two
of us will code data and identify themes identified. Ana-
lysis will be a rigorous, iterative and recursive process,
characterised by continual reading and re-reading of the
data until saturation of the constructs is achieved.
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Discussion
UK health and social care policy emphasises the import-
ance of people with dementia receiving an early diagno-
sis; obtaining information and support services quickly
and easily; being supported to live in their own homes;
and the development of high-quality, evidence-based in-
terventions. Providing community-based programmes
that aim to improve the quality of life for people with
dementia and their carers, training and supporting
carers, and tailoring interventions to individuals are seen
as key aspects of this national policy. COTiD-UK is an
evidence-based person-centred intervention that reflects
the current UK clinical and research priorities for sup-
porting people with dementia and their carers to remain
in their own homes.
High-quality, well-controlled intervention studies are es-
sential in order to develop effective services for people
with dementia and their carers. Adapting successful inter-
ventions from other countries serves as a good basis for
service, but successful implementation also requires con-
sideration of the national culture and service context.
This trial aims to determine the clinical and cost-
effectiveness of a community occupational therapy inter-
vention for people with dementia and their carers and
the feasibility of implementing it within the UK culture
and service context. The development and evaluation of
complex interventions such as COTiD-UK therefore
lend themselves to a mixed-methods approach as de-
scribed above.
If COTiD-UK is demonstrated to be clinically and cost
effective, it will have significant implications for the fu-
ture provision of services to people with mild to moder-
ate dementia and their carers across the UK.
Trial status
This trial is currently recruiting. Recruitment started in
September 2014 and is due to continue until the spring
of 2016.
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